Ferrylmyoglobin impairs secretion of VLDL triacylglycerols from stored intracellular pools: involvement of lipid peroxidation.
Ferrylmyoglobin (ferrylMb) may play a major role in vivo under certain pathological conditions. Preliminary experiments showed that ferrylmyoglobin induced a mild oxidative stress in rat hepatocytes, mainly reflected by early lipid peroxidation. One of the major functions of hepatocytes is the synthesis, secretion and distribution of lipids to other cells. The aim of this work was to examine whether ferrylMb affected the synthesis and secretion of triacylglycerols (TAG), and the possible involvement of lipid peroxidation on these effects. The heme protein completely impaired VLDL secretion, affecting both the lipid and apoB components of the lipoprotein particle. The incorporation of [(3)H]-oleate into newly synthesized diacylglycerol and TAG was not altered by ferrylMb. The co-treatment of cells with alpha-tocopherol prevented lipid peroxidation and concomitantly reverted VLDL TAG secretion to control values. Importantly, although ferrylMb dramatically blocked prelabeled TAG secretion, newly synthesized TAG secretion was not impaired. These data indicate that lipid peroxidation elicited by ferrylMb modulates the VLDL TAG secretion process, specifically affecting the stored intracellular TAG mobilization, rather than de novo synthesis. Apart from its potential role in vivo, ferrylmyoglobin constitutes a useful model for studying the interactions between lipid peroxidation and the specific TAG pool dependence for VLDL secretion.
Martínez
Rosa
R
Department of Physiology, Medicine School, University of the Basque Country, 48080-Bilbao, Spain.
Lacort
Mercedes
M
Ruiz-Sanz
José Ignacio
JI
Ruiz-Larrea
M Begoña
MB
D000818:Animals; D053299:Apolipoprotein B-100 / Q000378:metabolism; D004075:Diglycerides / Q000378:metabolism; D007700:Kinetics; D015227:Lipid Peroxidation / Q000187:drug effects / Q000502:physiology*; D008055:Lipids / Q000302:isolation & purification; D008079:Lipoproteins, VLDL / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008786:Metmyoglobin / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014168:Transferrin / Q000378:metabolism; D014280:Triglycerides / Q000037:antagonists & inhibitors / Q000378:metabolism*
D053299:Apolipoprotein B-100; D004075:Diglycerides; D008055:Lipids; D008079:Lipoproteins, VLDL; D014168:Transferrin; D014280:Triglycerides; C028048:ferrylmyoglobin; C030106:very low density lipoprotein triglyceride; D008786:Metmyoglobin